What's new in

FDA

Biotech

🔥 Bristol Myers Just Launched a Whole New Class of Myeloma Drug — and Priced It at $29,500 a Cycle

Bristol Myers Squibb's Zenbexus is the first CELMoD approved for multiple myeloma — cleared on a doubled deep-remission rate (41% vs 21%) and priced at $29,500 a cycle.

Biotech

🔥 Rejected Twice, Approved on the Third Try: The Tumor-Injected Virus That Just Cleared the FDA

After two rejections, Replimune's tumor-injected virus Tudriqev won accelerated FDA approval on August 6 — a 24.2% response rate in melanoma that had beaten standard immunotherapy.

Biotech

🔥 A $425,000 Kidney Drug Just Cleared the FDA — and It Hits Two Targets No One Had Hit at Once

Vera Therapeutics just won FDA accelerated approval for TRUTAKNA, the first dual BAFF/APRIL inhibitor for IgA nephropathy — priced at $425,000 a year. Here's why the two-target bet matters.